Rilapladib

TargetMol
Product Code: TAR-T16751
Supplier: TargetMol
CodeSizePrice
TAR-T16751-1mg1mg£146.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16751-5mg5mg£262.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16751-1mL1 mL * 10 mM (in DMSO)£382.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16751-10mg10mg£383.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16751-25mg25mg£597.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16751-50mg50mg£819.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16751-100mg100mg£1,091.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Rilapladib is a selective inhibitor of Lipoprotein-Associated Phospholipase A2(Lp-PLA2, IC50 = 230 pM) and an antagonist of the platelet activating factor receptor.
CAS:
412950-08-4
Formula:
C40H38F5N3O3S
Molecular Weight:
735.8
Pathway:
Metabolism
Purity:
0.9729
SMILES:
O=C1C=C(SCC=2C=CC=C(F)C2F)N(C=3C=CC=CC13)CC(=O)N(CC4=CC=C(C=C4)C=5C=CC(=CC5)C(F)(F)F)C6CCN(CCOC)CC6
Target:
Phospholipase

References

1. Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A? inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094. 2. Athanasios Papakyriakou, et al. Computational Investigation of Darapladib and Rilapladib Binding to Platelet Activating Factor Receptor. A Possible Mechanism of Their Involvement in Atherosclerosis. International Journal of Chemistry; Vol. 6, No. 1; 2014.